Identifying a biomarker for diagnosing Lewy Body Dementia before death
Peripheral Tissue Biomarker for Premortem Diagnosis of Lewy Body Dementia
This study is working on a new way to help doctors diagnose Lewy Body Dementia and Parkinson’s Disease Dementia by looking for specific proteins in easy-to-reach tissues like skin, so patients can get the right diagnosis earlier and improve their treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10894074 on NIH RePORTER |
What this research studies
This research aims to develop a diagnostic tool for identifying Lewy Body Dementia (DLB) and Parkinson’s Disease Dementia (PDD) using a new method that detects specific proteins in easily accessible tissues like skin and glands. Currently, diagnosing these conditions accurately can be challenging and often requires postmortem analysis. By utilizing a technique called real-time quaking induced conversion (RT-QuIC), the researchers hope to identify these biomarkers before death, allowing for earlier and more accurate diagnoses. This could significantly improve the management and treatment of patients suffering from these neurodegenerative diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals showing early symptoms of Lewy Body Dementia or Parkinson’s Disease Dementia.
Not a fit: Patients with other forms of dementia or neurodegenerative diseases that do not involve alpha-synuclein aggregates may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate diagnoses of Lewy Body Dementia and Parkinson’s Disease Dementia, improving patient care and treatment options.
How similar studies have performed: Previous research has shown promising results using similar biomarker detection methods, indicating potential for success in this novel approach.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Chen, Shu G. — University of Alabama at Birmingham
- Study coordinator: Chen, Shu G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.